ACG Postgraduate Course at 2023 Annual Meeting

• Treating the Moderate, Severe, and Refractory Crohn’s Patient: New Treatments Explored
  Sunanda V. Kane, MD, MSPH, FACG
  Apply current evidence-based strategies for treating refractory and severe Crohn’s disease.
• RCT Buzz for UC
  Millie D. Long, MD, MPH, FACG
  Discuss the most recent and up-to-date randomized, controlled data in ulcerative colitis care.
• The Non-IBD Colitis: Microscopic, Indeterminant, and Diverticular Disease-Associated Colitis
  Anita Afzali, MD, MPH, MHCM, FACG
  Explain the diagnosis and treatments of other non-IBD colitides commonly seen in GI practice.
• Healthcare Maintenance Needs in the IBD Patient
  Andres Yarur, MD
  Describe optimal preventive care in patients with inflammatory bowel disease.
• Panel Q & A

In With the New, While Managing the Old: How to Care for the Changing Face of Those With Liver Disease
Paul Y. Kwo, MD, FACG
Describe the changing epidemiology of liver disease and how to care for our growing populations of MASLD, alcohol-associated liver disease, and end-stage liver disease.

• IBS Pearls of Wisdom in Management: Beyond Individual Symptom Improvement
  Darren M. Brenner, MD, FACG
  Review the evidence-based guidelines and how they can help navigate patients through their global IBS symptoms.
• Taking Out the Word “Functional” in GI Disorders? Redefining Functional as DGBI
  Lin Chang, MD, FACG
  Explain why the term “DGBI” is more representative of many chronic GI diseases and how the multidimensional viewpoint leads to a patient-centered care model; how the diagnosis of DGBIs is a positive diagnosis based on ROME IV criteria rather than a diagnosis of exclusion and why.
• Bloating: Is It Really All Just a Visceral Sensation?
  Baharak Moshiree, MD, MSc, FACG
  Categorize the overlap of bloating seen in many disorders of gut-brain interaction and organic diseases that may need further investigations and varied treatments.
• ACG Updates on Gastroparesis and Functional Dyspepsia From Around the Globe
  Linda Anh B. Nguyen, MD, FACG
  Contrast the differences and similarities between the European and U.S. newly published guidelines.
• Panel Q & A

Saturday Optional Learning Luncheon Bonus Sessions

ACG has combined the popular in-person Learning Luncheons with on-demand access to the pre-recorded lectures for ALL 24 Learning Luncheon Bonus Sessions. Add this optional package to your Postgraduate Course registration for even more first-class education that provides an additional 18 hours of CME/MOC credit!

You must register for the Postgraduate Course in order to purchase the optional Learning Luncheon Bonus Sessions package. Both in-person and virtual registrants can purchase this add-on package. In-person attendees purchasing the package will be able to select a Saturday and a Sunday luncheon presentation to attend during the registration process.

1. Virtual Reality for Virtually Every GI Disease: Is VR Our Next Tesla?
   Brennan M. Spiegel, MD, MSHS, FACG
   Discuss how virtual reality can be a useful clinical tool for treating many functional disorders and other diseases and outline potential harm that can also come about from its use.
2. The Nutritional Approach to IBD, IBS, and MASLD: Benefits and Caveats
   Kate M. Scarlata, MPH, RDN, LDN, and Emily A. Haller, MS, RDN
   Assess an evidence-based approach to the role of diet and nutrition in the management of patients with these GI disorders and identify nutritional deficiencies that need to be addressed.
3. Evaluation of Abnormal Liver Tests and the Role of Endohepatology
   Joseph Ahn, MD, MS, MBA, FACG
   Summarize the algorithm and approach for evaluation of abnormal liver tests and review the role of endohepatology including EUS-guided liver biopsy and portal pressure management and how it fits in the evaluation of patients with liver disease.
4. What Your APP Can Bring to Your Practice
   Linda Anh B. Nguyen, MD, FACG, and Monica Nandwani, DNP, RN, FNP-BC
   Explain how subspecialized APPs can enhance a GI practice through clinical expertise, education, and research expertise.
5. Endoscopic Management and Resection of Difficult and Large Colon Polyps
   Rahul Pannala, MD
   Describe steps, tools, techniques, and options involved in the endoscopic management and resection of large and difficult colon polyps.
6. The Microbiome, Food Sensitivities, and Allergies: How to Evaluate What’s Real
   Brian E. Lacy, MD, PhD, FACG
   Discuss the currently available testing and research in this field with close attention to what’s fact and fiction.
7. Cyclic Vomiting Syndrome and Autonomic Dysfunction: Diagnosis and Treatment
   Thangam Venkatesan, MD
   Differentiate how cyclic vomiting syndrome and postural orthostatic tachycardia syndrome are two distinct disorders with varied treatments based on the most current evidence.
8. Treating the Non-Achalasia Esophageal Disorders
   C. Prakash Gyawali, MD, FACG
   Outline management tools for the care of patients with various non-achalasia esophageal disorders such as belching, hiccups, IEM, jackhammer esophagus, and distal esophageal spasm.
9. Evaluation and Management of Patients With Non-IBD Chronic Diarrhea
   Darren M. Brenner, MD, FACG
   Discuss the management of non-IBD diarrhea such as infectious, bile acid-induced, malabsorptive, carbohydrate intolerances, and others.
10. Pelvic Floor Dysfunction: How Physical Therapists and Providers Can Co-Manage
    Jose M. Remes Troche, MD
    Explain the techniques used by the physical therapist in treating pelvic floor disorders, such as dyssynergic defecation and impaired propulsion once a correct diagnosis is made by the expert gastroenterologist.
11. C. difficile: Current Advancements
    Paul Feuerstadt, MD, FACG
    Outline current and future therapies for initial and refractory C. difficile including fecal microbial transplantation, antibiotics, and others.
12. The Risk of PPI Therapy: What’s the Real Story and Are There Better Alternatives Now With PCABs?
    Paul Moayyedi, MB ChB, PhD, MPH, FACG
    Analyze the risks, benefits, and controversies of PPI use and provide an evidence-based approach for incorporating potassium-competitive acid blockers into clinical practice.

Symposium A: Obesity and Liver Disease: What’s the Latest?
Moderator: Arun J. Sanyal, MD

• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Future of Antifibrotics
  Arun J. Sanyal, MD
  Discuss current and future treatment modalities for MASLD.
• Obesity and Medical Management for the GI Doc
  Jennifer Phan, MD
  Explain the medical management of obesity and ways in which the gastroenterologist can get involved.
• Endobariatic and Surgical Management of Obesity
  Allison R. Schulman, MD, MPH
  Explain evidence-based management of endobariatic and surgical interventions in patients with obesity - where are we now and what is in the future?
• Panel Q & A

Symposium B: Pancreas: Management Guide for the Practicing Clinician
Moderator: Vivek Kaul, MD, FACG

• Acute Pancreatitis: Etiology and Management in 2023
  Vivek Kaul, MD, FACG
  Explain the various etiologies of acute pancreatitis along with guideline-based management strategies.
• Screening Patients for High-Risk Pancreatic Cancer: When and Who to Evaluate?
  Tamas A. Gonda, MD
  Discuss the indication, ideal population, role of genetic testing, and radiologic/endoscopic modalities for screening of pancreatic cancer.
• Chronic Pancreatitis: Evaluation, Management, and Emerging Therapies
  Gregory A. Cote, MD, MS
  Describe the etiology and evidence-based endoscopic/surgical and medical management of patients with chronic pancreatitis; discuss when a patient should be referred for surgery or other therapies such as stem cell transplantation.
• Panel Q & A

Symposium C: Autoimmune and Dysbiotic GI Diseases From Celiac Disease to Eosinophilic Gastrointestinal Disorders: What Is the Scoop?
Moderator: Maria I. Vazquez-Roque, MD

• Are SIBO and IBS Autoimmune Responses to Intestinal Dysbiosis?
  Ali Rezaie, MD, MSc
  Discuss the role of the microbiome in disorders such as IBS, FD, and other related syndromes, and explain how the microbial species may differ in the IBS subtypes.
• Are EGIDS a Spectrum of Food Disorders or Intolerances?
  Maria I. Vazquez-Roque, MD, MS
  Explain what eosinophilic gastrointestinal disorders are and whether, based on current data, they are immune-related disorders or related to food allergies.
• Refractory Celiac Disease: What to Do When a Gluten-Free Diet Doesn’t Cure
  Alberto Rubio-Tapia, MD
  Outline the treatment of refractory celiac disease with interpretations of noncompliance versus refractory disease.
• Panel Q & A

• 45 Is the New 50: The New Screening Update and How We Meet the Demands
  Aasma Shaukat, MD, MPH, FACG
  Discuss the new colon cancer screening guidelines from the U.S. and Canada and how the new demands will be met.
• Lower GI Bleeding: An Update
  Neil Sengupta, MD, FACG
  Outline the current approach to the patient with lower GI bleeding and discuss best practice guidelines, including “to scope or not to scope?”
• SSLs: Detection, Resection, and Follow-Up
  Shahnaz Sultan, MD, MHSc, FACG
  Describe the endoscopic approach to sessile serrated lesions, as well as mechanisms for resection and follow-up.
• Panel Q & A